Recent advances in drug discovery for diabetic kidney disease. (3rd April 2021)

• Record Type: Journal Article
• Authors: Danta, Chhanda Charan; Boa, Andrew N.; Bhandari, Sunil; Sathyapalan, Thozhukat; Xu, Shang-Zhong
• Is Part Of: Expert opinion on drug discovery. Volume 16:Number 4(2021)
• Page Start: 447
• Page End: 461
• Publication Date: 2021-04-03
• Subjects: Diabetic complications -- diabetic nephropathy -- drug discovery -- endothelin receptor blockers -- oxidative stress -- renin-angiotensin-aldosterone system -- SGLT-2 inhibitors; 615.1
• DOI: 10.1080/17460441.2021.1832077
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction: Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD), and 40% of patients with diabetes develop DKD. Although some pathophysiological mechanisms and drug targets of DKD have been described, the effectiveness or clinical usefulness of such treatment has not been well validated. Therefore, searching for new targets and potential therapeutic candidates has become an emerging research area. Areas covered: The pathophysiological mechanisms, new drug targets and potential therapeutic compounds for DKD are addressed in this review. Expert opinion: Although preclinical and clinical evidence has shown some positive results for controlling DKD progression, treatment regimens have not been well developed to reduce the mortality in patients with DKD globally. Therefore, the discovery of new therapeutic targets and effective target-based drugs to achieve better and safe treatment are urgently required. Preclinical screening and clinical trials for such drugs are needed.